MannKind Corporation announced that Steven B. Binder will retire from his position as Chief Financial Officer, effective April 22, 2024. Mr. Binder plans to remain at the company through the end of the year as Executive Vice President, Special Projects. Christopher Prentiss has been appointed as Chief Financial Officer, effective April 22, 2024.

Mr. Prentiss will be a member of the company?s executive leadership team and will report to Michael Castagna, Chief Executive Officer. Chris has over 20 years of experience serving in financial leadership positions within the biopharma industry in both private and public companies. Since September 2022, Mr. Prentiss has served as Chief Financial Officer of ADARx Pharmaceuticals Inc., where he helped to raise nearly $250 million in funding.

Between April 2015 and November 2021, he held a series of finance positions of increasing responsibility at the commercial-stage biotech company Adamas Pharmaceuticals Inc., culminating in Chief Financial Officer. His responsibilities at Adamas included finance, accounting, investor relations, information technology and facilities. During his tenure, the company launched GOCOVRI® (in 2018) as well as acquired OSMOLEX® ER.

At the time Adamas was acquired by Supernus Pharmaceuticals Inc. His earlier career also included senior financial roles at InterMune Inc., Dynavax Technologies Corporation and MannKind. Mr. Prentiss began his career in the assurance practice at KPMG LLP. A licensed CPA (inactive) in California, he earned his Bachelor of Science degree in Accounting from Loyola Marymount University and an MBA from Indiana University?s Kelley School of Business.